Department of Neurosciences, Neurology Unit, Azienda Ospedaliero-Universitaria of Parma, Italy.
J Neurol Sci. 2011 Nov 15;310(1-2):286-8. doi: 10.1016/j.jns.2011.08.012. Epub 2011 Sep 1.
The co-morbidity between Parkinson's disease (PD) and restless legs syndrome (RLS) is currently controversial, mainly because in most of the studies so far conducted, the patients were already on therapy with dopamine(DA)ergic drugs. This study has been carried out to assess the prevalence of RLS in de novo PD patients previously unexposed to DAergic drugs.
One hundred nine cognitively unimpaired outpatients with PD (70M/39F), mean age 66.89 years±9.37 SD were included in the study. The mean duration of PD was 15.81 months±11.24 SD, and the median Hoehn and Yahr (H&Y) stage was 2 (range 1.5-3). All patients underwent interview to assess the occurrence of overall life-time and current "primary" form of RLS according to the criteria of the International RLS Study Group (IRLSSG). One hundred sixteen age and sex matched subjects (74M/42F, mean age 66.52.years±8.65 SD) free from a history of neurological diseases, were taken as controls and likewise interviewed. "Secondary" forms of RLS in both patients and controls were subsequently excluded.
No significant difference was found (chi-square test) in the frequency of overall life-time and of current "primary" RLS between PD patients and controls (6 out of 109 versus 5 out of 116 and 3 out of 109 versus 3 out of 116, respectively).
This survey does not support the concept of a co-morbid association between the two conditions and confirm indirectly the findings of previous studies reporting the onset of RLS after diagnosis of PD has been made in the great majority of patients and so likely on ongoing DAergic treatment. Therefore, we speculate that RLS occurring in these patients could be related to DAergic therapy for PD.
帕金森病(PD)与不宁腿综合征(RLS)之间的共病关系目前存在争议,主要是因为到目前为止进行的大多数研究中,患者已经接受了多巴胺(DA)能药物治疗。本研究旨在评估先前未接受 DA 能药物治疗的新发 PD 患者中 RLS 的患病率。
本研究纳入了 109 例认知无障碍的门诊 PD 患者(70 名男性/39 名女性,平均年龄 66.89 岁±9.37 岁标准差)。PD 的平均病程为 15.81 个月±11.24 个月,中位数 Hoehn 和 Yahr(H&Y)分期为 2 级(范围 1.5-3 级)。所有患者均接受访谈,根据国际 RLS 研究组(IRLSSG)的标准评估总体终生和当前“原发性”RLS 的发生情况。选择 116 名年龄和性别匹配的受试者(74 名男性/42 名女性,平均年龄 66.52.岁±8.65 岁标准差)作为对照组,并进行同样的访谈。随后排除了患者和对照组中的“继发性”RLS。
PD 患者和对照组在总体终生和当前“原发性”RLS 的发生率方面无显著差异(卡方检验)(6/109 与 5/116 和 3/109 与 3/116)。
本调查不支持这两种疾病存在共病关系的概念,并间接地证实了先前的研究结果,即大多数患者在诊断为 PD 后出现 RLS,因此可能正在接受 DA 能药物治疗。因此,我们推测这些患者中出现的 RLS 可能与 PD 的 DA 能治疗有关。